“HER2-Negative Breast Cancer Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the HER2-Negative Breast Cancer Market.
The HER2-Negative Breast Cancer Pipeline report embraces in-depth commercial, regulatory, and HER2-Negative Breast Cancer clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging HER2-Negative Breast Cancer drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report provides detailed insights into the emerging therapies for HER2-Negative Breast Cancer treatment and the aggregate therapies developed by major pharma companies.
It accesses the different HER2-Negative Breast Cancer therapies segmented into early-stage, mid-stage, and late-stage clinical development.
It outlines the major HER2-Negative Breast Cancer companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the HER2-Negative Breast Cancer drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the HER2-Negative Breast Cancer therapeutic market.
Analysis of Emerging HER2-Negative Breast Cancer Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Learn How the HER2-Negative Breast Cancer Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @
HER2-Negative Breast Cancer Therapeutics Landscape
There are approx. 85+ key companies developing therapies for HER2-Negative Breast Cancer. Currently, Jiangsu HengRui Medicine is leading the therapeutics market with its HER2-Negative Breast Cancer drug candidates in the most advanced stage of clinical development.
HER2-Negative Breast Cancer Companies Actively Working in the Therapeutic Market Include:
Jiangsu HengRui Medicine
Chia Tai Tianqing Pharmaceutical
Eli Lilly and Company
And Many Others
Emerging and Marketed HER2-Negative Breast Cancer Drugs Covered in the Report Include:
Capivasertib + Fulvestrant: AstraZeneca
Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. Capivasertib in combination with fulvestrant is currently in phase III clinical studies for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy.
Dalpiciclib: Jiangsu HengRui Medicine
Dalpiciclib (formerly SHR 6390) is an orally administered small molecule and selective cyclin-dependent kinase (CDK)-4/6 inhibitor. Dalpiciclib in Combination with Letrozole or Anastrozole or Fulvestrant is in Phase III clinical evaluation in patients with HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer.
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and HER2-Negative Breast Cancer Companies Working in the Market @ https://www.delveinsight.com/sample-request/her2-negative-breast-cancer-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. HER2-Negative Breast Cancer Treatment Patterns
4. HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. HER2-Negative Breast Cancer Late Stage Products (Phase-III)
7. HER2-Negative Breast Cancer Mid-Stage Products (Phase-II)
8. HER2-Negative Breast Cancer Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. HER2-Negative Breast Cancer Discontinued Products
13. HER2-Negative Breast Cancer Product Profiles
14. Major HER2-Negative Breast Cancer Companies in the Market
15. Key Products in the HER2-Negative Breast Cancer Therapeutics Segment
16. Dormant and Discontinued Products
17. HER2-Negative Breast Cancer Unmet Needs
18. HER2-Negative Breast Cancer Future Perspectives
19. HER2-Negative Breast Cancer Analyst Review
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Dense Deposit Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dense Deposit Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dense Deposit Disease market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States